Does a GLP-1 Booster Work? What the Evidence Says (October 2026)

01 · The verdict

So, does a GLP-1 booster work?

A GLP-1 booster does not work like a GLP-1 medicine, and you should not expect medicine-level results from one. These products are dietary supplements, usually built around plant extracts, fibre or similar ingredients. They are not medicines, they are not regulated for this use, and they have no comparable trial evidence.¹ That is different from saying a supplement can never do anything at all. It means nobody has shown, in trials of the kind that licensed medicines go through, that a booster delivers meaningful, reliable weight loss.

The word 'booster' is also misleading. It implies the product raises your own GLP-1 hormone to a useful level. Licensed treatments do something far more direct: they are designed to activate the GLP-1 receptor itself. Tirzepatide, the active ingredient in Mounjaro, activates both GIP and GLP-1 receptors.¹ A capsule of plant extract is not in that category, and marketing language does not close the gap.

If you want more detail on specific product types, our guides on how these supplements are assessed and on booster pills go product by product.

02 · Your decision

The two decisions you are really facing

The first decision is whether you are looking for a supplement or for treatment. If your goal is meaningful weight loss and you meet the licensing criteria, the evidence points to licensed medicines, not boosters. If your goal is general healthy eating support, a supplement is a personal choice, but it should never be treated as a substitute for treatment, and it should never be added on top of a GLP-1 medicine without asking your prescriber.

The second decision is which licensed route suits you.

A booster sits in the first row: low-cost, easy to buy, and with no assessment of whether it is suitable for you. Every licensed option in the table involves a prescriber who checks your health and other medicines.

03 · Next step

What to do next

If you meet the criteria and want a licensed treatment, the pathway is short. You complete a free online consultation, a GPhC-registered prescriber reviews it, and unsuitable orders are refunded automatically. Our weight loss clinic explains the options. The Mounjaro pen starts with a 2.5mg pen at £169.99 per month; a new customer's first 2.5mg pen costs £129.99 with code FIRST40.

If you are not sure whether you qualify, start with the consultation rather than a supplement. The questionnaire is free, with no obligation, and the prescriber can tell you honestly whether treatment is suitable. Prices checked 10 October 2026.

04 · What boosters contain

What 'GLP-1 boosters' actually contain

GLP-1 boosters are dietary supplements, and the ingredient lists tend to follow the same pattern. Berberine, green tea extract and fibre blends appear again and again, often alongside vitamins and botanical extracts. The marketing leans on phrases such as 'natural GLP-1', 'nature's Ozempic' or 'GLP-1 support'. Those phrases sound clinical, but they are branding, not a regulatory category.

The distinction that matters is legal and practical. Supplements of this kind are not medicines. They are not regulated for this use, and they have no comparable trial evidence to the licensed treatments.¹ A licensed medicine has to show, in controlled trials, what it does and what harm it may cause before it reaches patients. A supplement generally does not have to demonstrate that it works for weight loss before it is sold. That single difference explains most of the confusion online.

Another point to be aware of is that dosing is not standardised across supplements. Two products with the same name on the front can contain very different amounts of the same ingredient, and there is no prescriber deciding what amount suits you.

Cost is part of the appeal. These products are low-cost and available cheaply without assessment, which is why they spread so fast on social media. But low cost is a different thing from good value. If a product does not deliver the effect it implies, the money is spent on something that does not do what you bought it for, and the months you spend relying on it are months without effective support.

It is also worth separating two claims that marketers often blur. The first is 'this ingredient does something in the body'. Many plant compounds do have some biological activity, and that is not in dispute. The second is 'this product raises GLP-1 enough to cause the weight loss seen with prescription medicines'. That second claim is the one with no comparable trial evidence behind it, and it is the one the word 'booster' quietly asks you to believe.

If you want to read about specific formats, we cover booster tablets and the wider category of GLP-1 boosters separately. The short version for each is the same: the product is a supplement, the claims go further than the evidence, and you remain better served by a licensed route if you meet the criteria.

Finally, patches, drops, gummies and sprays follow the same logic as capsules. A different delivery format does not turn a supplement into a medicine. Look for a licence, a named prescriber and published trials. If none of the three is present, treat dramatic weight-loss claims with caution.

05 · How real GLP-1s work

How a real GLP-1 medicine works

A licensed GLP-1 medicine works by activating gut-hormone receptors directly, rather than hoping the body makes more of its own hormone. Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.

In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. That is the useful way to understand the effect: the medicine makes it easier to eat less, and the diet and activity changes do the rest. Mounjaro is used alongside a reduced-calorie diet and increased physical activity, not instead of them.¹

This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide, the active ingredient in Wegovy and Ozempic.¹ Both are licensed, effective treatments, and which one suits a particular person depends on health profile, tolerance and prescriber advice.

Why does this matter for the booster question? Because the 'boost' idea assumes you can nudge your own hormone upward with an ingredient. The medicines do something much more specific: they are engineered to bind the receptors and produce a sustained, measurable response. The prescription route also lets a prescriber start low and step up gradually, which helps manage digestive side effects. A supplement has no such structure.

Mounjaro comes as a once-weekly injectable pre-filled multi-dose pen, the KwikPen, in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ Treatment starts at the lowest strength and steps up after at least four weeks as tolerated, which is why the early weeks are described as an adjustment phase rather than the point at which most weight loss happens.

There is also a practical point on how long the medicine stays in the body. Tirzepatide takes roughly four to five weeks to clear the system after a final dose, there is no way to speed this up, and nothing needs doing while it clears.¹ That tells you something about how these medicines are designed to act: steadily and over time, not as a quick lift from a capsule.

Once you see the mechanism, the claim 'my supplement works like Mounjaro' looks different. Receptor-level drug action is the thing being claimed; a plant extract has not been shown to do it. You can read how the new oral option works in our guide to how Foundayo works, which explains the GLP-1 mechanism in plain language.

06 · What trials show

What the trial evidence shows for licensed treatments

Licensed GLP-1 treatments have large, published trials; boosters do not. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.² That tells you something a supplement label never will: how many people in a controlled trial responded, not just the average.

Semaglutide has its own trial record. In the STEP 1 trial, adults on semaglutide 2.4mg (Wegovy) lost on average 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.⁹ Notice the structure in both cases: a named trial, a duration, a comparison group. Those three features are what separate evidence from marketing.

For a worked example, for someone starting at 100 kg, 20.9% is about 21 kg. That is an illustration of arithmetic on the trial average at the highest dose, not a forecast of your own result. Trial averages do not predict your own result, and many people will lose less or more.

The same discipline applies in the other direction. When a booster page quotes a dramatic result, ask which trial it came from, how long it ran, who was in it, and what the comparison group did. For supplements, those questions usually go unanswered. The honest summary is that there is no comparable trial evidence for them.¹

Pace matters as well. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.

Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹ That built-in review is another thing a supplement cannot offer: a clinical point at which someone checks whether the treatment is doing its job.

The takeaway is not that every person gets the same outcome from a licensed treatment. It is that the claims can be checked, and they come with a named evidence base. A booster's claims cannot be checked in the same way.

07 · Head-to-head evidence

Why direct comparisons matter

SURMOUNT-5 is the first large head-to-head trial of tirzepatide and semaglutide for weight loss, and a useful reminder of how rare real head-to-head evidence is. In SURMOUNT-5, adults on tirzepatide lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4mg (Wegovy).¹⁵ Both are effective, licensed treatments; which suits you depends on your health profile, tolerance and prescriber advice, not the headline number alone.

In SURMOUNT-5, 751 adults took tirzepatide or semaglutide 2.4mg for 72 weeks. At least 10% of body weight was lost by 81.6% on tirzepatide vs 60.5% on semaglutide; at least 15% by 64.6% vs 40.1%; at least 20% by 48.4% vs 27.3%; at least 25% by 31.6% vs 16.1%. Average loss was 22.8 kg vs 15.0 kg.¹⁵

This sort of trial design is exactly what a supplement has never been put through. No booster has been compared against a licensed GLP-1 medicine in a trial like this, so there is nothing credible to set beside these figures. When a website says its product is 'as good as' a prescription medicine, ask for the trial. If none is named, the claim is not evidence-based.

It also helps to know what not to do with numbers. Do not set the results of two different trials side by side as if they were head to head. Different people, durations and doses make that comparison unreliable.

The same caution applies to the claim that a booster can 'enhance' a prescription medicine. If you are on treatment already, you can read why we advise against adding supplements in our guide on combining a booster with Mounjaro.

Side effects are part of an honest comparison too. In STEP 1, gastrointestinal side effects were reported by 74.2% of people on semaglutide 2.4mg, compared with 47.9% on placebo. 7.0% stopped treatment because of side effects, compared with 3.1% on placebo.⁹ That is the downside of a medicine that works: it acts on the digestive system, and many people notice it.

These figures show what real evidence looks like, so that you can hold any booster claim up against it and see how much is missing.

08 · GLP-1 tablets now

If you want a pill, licensed tablets now exist

If what attracts you to a booster pill is avoiding injections, there are now licensed GLP-1 weight-loss tablets. There is no tablet form of Mounjaro, because tirzepatide is injection-only in the UK. Two GLP-1 weight-loss tablets are now licensed in the UK: Wegovy tablets (oral semaglutide, made by Novo Nordisk) and Foundayo (orforglipron, made by Eli Lilly). They are different medicines from Mounjaro, with their own dosing, eligibility checks and trial results, and both are prescription-only.²⁰²¹

Wegovy tablets contain semaglutide, the same active ingredient as the Wegovy injection, taken as one tablet once a day. They are licensed for weight management in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity.²⁰ The routine is strict: the tablet must be taken on an empty stomach after fasting for at least 8 hours, swallowed whole with a sip of water (up to half a glass, about 120ml), and you then wait at least 30 minutes before eating, drinking or taking other tablets.

In the OASIS 4 trial, adults taking semaglutide 25mg tablets for 64 weeks lost on average 13.6% of their body weight, compared with 2.2% on placebo.²² The most common side effects are digestive: nausea, vomiting, diarrhoea, constipation, indigestion and stomach pain, along with headache and tiredness.²² You can see current options on the Wegovy pill page.

Foundayo contains orforglipron, a once-daily GLP-1 tablet. Unlike Wegovy tablets it can be taken at any time of day, with or without food and without water restrictions; the tablet is swallowed whole.²¹ It is licensed for the same BMI groups as Wegovy tablets. Treatment starts at 0.8mg once daily, then steps up to 2.5mg and 5.5mg, and then to 9mg, 14.5mg or 17.2mg depending on response and tolerability, with at least 30 days at each dose; 17.2mg once daily is the maximum.²¹ See the Foundayo (orforglipron) page for current prices.

In the ATTAIN-1 trial of 3,127 adults without type 2 diabetes, people taking the highest dose of orforglipron for 72 weeks lost on average 12.4% of their body weight, compared with 0.9% on placebo.²³ The trial used capsules, and the UK 17.2mg tablet corresponds to the highest trial dose, so the tablet and capsule doses are not comparable milligram for milligram.²³

No trial has compared Mounjaro directly with either tablet, so results from separate trials, with different people, durations and doses, should not be set against each other as if they were head to head. The practical differences matter as much as the averages: Wegovy tablets need a strict empty-stomach routine every morning, Foundayo has no food or water rules, and Mounjaro needs one injection a week. A prescriber will check which option is suitable for your health, your other medicines and your routine.

The key point is that a pill you can buy as a 'booster' is not the same thing as a pill a prescriber supplies. Only the second has been through licensing, with dosing, eligibility checks and trial data that you can read.

09 · Safety and stacking

Safety: stacking, interactions and side effects

The safest rule is simple: never run two GLP-1 products together, and never add an unregulated 'booster' to a prescribed medicine. Mounjaro must not be combined with other GLP-1 medicines, unlicensed 'research' peptides (such as retatrutide, which has no UK licence), or compounded copies. These combinations have no safety data and no regulated supply chain. If something promises faster results outside a licensed pathway, that is the warning sign.¹

That warning covers sellers who offer to supply prescription-strength products without a consultation or prescription, and listings that promise specific results. A genuine UK pharmacy will ask about your health and other medicines before supplying anything. If a site does not, treat that as a red flag and consider the risk of counterfeit products. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting problems.⁷

Contraception is one specific interaction worth knowing. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. This applies to the pill only; implants, coils and injections are unaffected.¹ Foundayo may make oral contraceptive pills less effective: switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase.²¹

Pregnancy has its own rule: Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly.¹ Current prescribing information indicates minimal transfer of tirzepatide into breast milk, so discuss breastfeeding with your prescriber so the decision reflects your circumstances.¹

What are the downsides of GLP-1 medicines? The most common are digestive. In STEP 1, gastrointestinal side effects were reported by 74.2% of people on semaglutide 2.4mg, compared with 47.9% on placebo.⁹ Wegovy tablets add headache and tiredness, and list gallstones and hair loss as common.²² These are the reasons a prescriber reviews you before and during treatment.

If you notice a new symptom on any medicine, speak to your prescriber and report it through the Yellow Card scheme.¹⁹ A supplement has no equivalent follow-up, and its effects on your body are not tracked in the same way. That is another quiet cost of relying on a booster: if it causes a problem, or interacts with something you take, nobody is assessing it for you.

None of this means supplements are always dangerous. It means they come without the safeguards that prescribed treatment carries, so the burden of judging safety falls on you, and there is little evidence to help you judge.

10 · Dopamine and mood

GLP-1, dopamine and why people feel different

People often ask whether GLP-1 affects dopamine and why it can make them feel better. The established actions of tirzepatide are on appetite, stomach emptying and the body's response to insulin. Regulators have looked specifically at whether GLP-1 medicines are linked to low mood or suicidal thoughts: the EMA's safety committee reviewed the evidence and concluded in 2024 that it does not support a causal link, and the MHRA keeps this under continuous review.

Feeling better on treatment has plenty of ordinary explanations that do not need a brain-chemistry story. Feeling fuller and less preoccupied with food can lift confidence. Making progress can be motivating. Sleep, movement and eating patterns often improve together. None of that is a claim about a particular pathway; it is simply a reminder that how you feel on treatment is shaped by many things.

If you are worried about low mood, low motivation or changes in how you feel, speak to your GP or prescriber.

If you notice low mood or new or worsening mood symptoms while on a GLP-1 medicine, tell your prescriber and seek help promptly. If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night.¹⁹

It is also worth being sceptical of any booster that claims to act on dopamine, cravings and GLP-1 all at once. Those are broad promises, and they are not backed by comparable trial evidence. A licensed medicine's claims are narrower and checked; a supplement's claims tend to be wide and unchecked.

For the practical question of how to feel better while losing weight, the consultation is a good place to raise it.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

12 · NHS and private routes

NHS and private routes to a licensed treatment

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

Your first step on the NHS is a conversation with your GP. NHS access to Wegovy runs through specialist weight-management services, so ask your GP what is available in your area. A supplement is not part of either pathway.

If you choose a private route, the process is straightforward and regulated. EverydayMeds is a GPhC-registered UK online pharmacy (registration GPhC 9012878), and Mounjaro is supplied only after an online consultation reviewed by a GPhC-registered prescriber.¹² We source through official LillyDirect supply, direct from Eli Lilly's UK distribution, with genuine KwikPens and all six doses stocked.

Ordering works in clear steps. First, you complete a free online consultation: a short health questionnaire, no charge, no obligation. Second, a GPhC-registered prescriber reviews it. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Third, our registered pharmacy dispenses and dispatches, with same-day dispatch when ordered by 3pm. Delivery is free, next-day, tracked and temperature-controlled; Saturday delivery is £14.99.

On cost, a first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg, at standard prices. A new customer's first order is £40 less with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices.

Payment options include Visa, Mastercard, Klarna and pay-monthly options, with no subscriptions, and repeat orders re-check suitability, with no auto-shipping. Needles, a sharps bin and injection guidance are included with every order. Our team is available Monday to Friday, 9am to 5pm, at support@everydaymeds.co.uk, via the account portal chat, or by phone on 0333 207 0413, and aftercare includes ongoing monthly reviews and side-effect support.

Compared with buying a booster, the difference is not just effectiveness. It is accountability: a named pharmacy on the GPhC register, a prescriber who reviews you, and a follow-up process.

Mounjaro is a prescription-only medicine, used alongside a reduced-calorie diet and increased physical activity. Individual results vary, and this page is information, not a substitute for medical advice.